Cibotercept - Keros Therapeutics
Alternative Names: KER-012; RKER 012Latest Information Update: 26 Jun 2024
At a glance
- Originator Keros Therapeutics
- Class Antihypertensives; Heart failure therapies; Immunoglobulin Fc fragments; Osteoporosis therapies; Recombinant fusion proteins
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic heart failure; Pulmonary arterial hypertension
- Phase I Osteoporosis
- Preclinical Osteogenesis imperfecta
Most Recent Events
- 17 May 2024 Pharmacodynamics data from a preclinical trial in Pulmonary arterial hypertension presented at 120th International Conference of the American Thoracic Society(ATS-2024)
- 28 Feb 2024 Phase-II clinical trials in Chronic heart failure (unspecified route)
- 31 Dec 2023 Keros Therapeutics has patent protection for cibotercept in USA, as of December 2023